A retrospective analysis of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma
Latest Information Update: 10 Aug 2021
Price :
$35 *
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Therapeutic Use
- 10 Aug 2021 New trial record